Adage Capital Partners
VTYX

Adage Capital Partners’s Ventyx Biosciences VTYX Stock Holding History

Adage Capital Partners’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-375,000
Closed -$3.39M – 1079
2025
Q4 		$3.39M Buy
+375,000
New +$2.8M 0.01% 800
2024
Q2 		– Sell
-1,265,050
Closed -$6.96M – 949
2024
Q1 		$6.96M Buy
1,265,050
+665,050
+111% +$3.04M 0.01% 661
2023
Q4 		$1.48M Sell
600,000
-387,970
-39% -$3.68M ﹤0.01% 750
2023
Q3 		$34.3M Buy
987,970
+895,000
+963% +$30.9M 0.08% 262
2023
Q2 		$3.05M Sell
92,970
-411,945
-82% -$14.2M 0.01% 716
2023
Q1 		$16.9M Sell
504,915
-916,330
-64% -$35.6M 0.04% 478
2022
Q4 		$46.6M Buy
1,421,245
+1,021,245
+255% +$30.2M 0.11% 223
2022
Q3 		$14M Buy
+400,000
New +$8.86M 0.03% 539

Other funds holding VTYX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Adage Capital Partners's VTYX Position: Q1 2026 in Review

Adage Capital Partners sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 375,000 shares — an estimated $3.39M sold.

Adage Capital Partners first reported a position in VTYX in Q3 2022 and held it in 8 quarters. The position peaked at $46.6M in Q4 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.

  • Adage Capital Partners reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
  • Adage Capital Partners sold 375,000 Ventyx Biosciences shares in Q1 2026, an estimated $3.39M.
  • Adage Capital Partners first reported a position in Ventyx Biosciences in Q3 2022 and held it in 8 quarters.
  • Adage Capital Partners's Ventyx Biosciences position peaked at $46.6M in Q4 2022.
  • 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.